NSAID therapy

ApprovedSmall molecule

RRabin Medical Center

NSAID therapy is one of 15 small molecule programs targeting Pericarditis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PericarditisActive, not recruiting

PericarditisApproved

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Pericarditis

#DrugCompanyPhaseTrials

Colcrys

Alnylam Pharmaceuticals

Approved

6 2

Bayer Aspirin

Bayer

Approved

1 3

Epidiolex

Jazz Pharmaceuticals

Approved

—4

Plaquenil

Alnylam Pharmaceuticals

Phase 3

1 5

Rayos

RRoxane Laboratories

Phase 3

1 6

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

RPH-104

UUnknown Sponsor

Phase 3

3 8

Kineret

SSwedish Orphan Biovitrum

Phase 2

4 9

NSAID therapy

RRabin Medical Center

Approved

1 10

Spikevax

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pericarditis1 trial

Dexamethasone Compared to Non-steroidal Anti-inflammatory Drugs in the Treatment of Acute Pericarditis

Terminated·RRabin Medical Center·Phase 4·NCT04323280·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NSAID therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NSAID therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NSAID therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rabin Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: RRabin Medical Center

NSAID therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pericarditis1 trial

References

Drug Info

Quick Facts

Related News